MX2021000043A - Activadores de la respuesta a proteinas desplegadas. - Google Patents

Activadores de la respuesta a proteinas desplegadas.

Info

Publication number
MX2021000043A
MX2021000043A MX2021000043A MX2021000043A MX2021000043A MX 2021000043 A MX2021000043 A MX 2021000043A MX 2021000043 A MX2021000043 A MX 2021000043A MX 2021000043 A MX2021000043 A MX 2021000043A MX 2021000043 A MX2021000043 A MX 2021000043A
Authority
MX
Mexico
Prior art keywords
cancer cells
erî
activators
small molecules
resistant
Prior art date
Application number
MX2021000043A
Other languages
English (en)
Inventor
Paul J Hergenrother
David J Shapiro
Matthew W Boudreau
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of MX2021000043A publication Critical patent/MX2021000043A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Abstract

Conjunto de biomoduladores ERa de moléculas pequeñas que destruyen las células cancerosas de mama, ovario y endometrio ERa positivas resistentes a la terapia. Estas pequeñas moléculas tienen un mayor potencial terapéutico debido a la mayor capacidad para destruir las células de cáncer de mama resistentes a la terapia en comparación con BHPI y otras terapias convencionales (terapias endocrinas, tamoxifeno y fulvestrant/ICI). Los nuevos compuestos no solo inhiben la proliferación de las células cancerosas, sino que también realmente las destruye, lo que evita la reactivación de los tumores años después.
MX2021000043A 2018-07-03 2019-07-01 Activadores de la respuesta a proteinas desplegadas. MX2021000043A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862693641P 2018-07-03 2018-07-03
PCT/US2019/040058 WO2020009958A1 (en) 2018-07-03 2019-07-01 Activators of the unfolded protein response

Publications (1)

Publication Number Publication Date
MX2021000043A true MX2021000043A (es) 2021-03-25

Family

ID=69059783

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000043A MX2021000043A (es) 2018-07-03 2019-07-01 Activadores de la respuesta a proteinas desplegadas.

Country Status (22)

Country Link
US (3) US20210276951A1 (es)
EP (1) EP3817741A4 (es)
JP (1) JP2021529757A (es)
KR (1) KR20210027382A (es)
CN (1) CN112423743A (es)
AU (1) AU2019299221A1 (es)
BR (1) BR112020025591A2 (es)
CA (1) CA3103958A1 (es)
CL (1) CL2020003423A1 (es)
CO (1) CO2020016690A2 (es)
CR (1) CR20210060A (es)
DO (1) DOP2020000256A (es)
EA (1) EA202190146A1 (es)
EC (1) ECSP20084330A (es)
IL (1) IL279429A (es)
JO (1) JOP20200344A1 (es)
MA (1) MA53105A (es)
MX (1) MX2021000043A (es)
PE (1) PE20210662A1 (es)
PH (1) PH12020552223A1 (es)
SG (1) SG11202012902WA (es)
WO (1) WO2020009958A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20210060A (es) 2018-07-03 2021-04-08 Univ Illinois Activadores de la respuesta a proteínas desplegadas
WO2021222738A1 (en) * 2020-05-01 2021-11-04 The Board Of Trustees Of The University Of Illinois Compounds for estrogen receptor positive cancers
WO2022020605A1 (en) * 2020-07-23 2022-01-27 The Board Of Trustees Of The University Of Illinois Treatment of metastasized estrogen receptor positive breast cancer
WO2022032146A1 (en) * 2020-08-07 2022-02-10 Systems Oncology, Llc Methods for inhibiting growth of era positive cancers
WO2022087234A1 (en) * 2020-10-23 2022-04-28 The Board Of Trustees Of The University Of Illinois Anticancer compounds selective for er-positive cancers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487792A1 (en) 2002-03-15 2004-12-22 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
JP4989976B2 (ja) * 2004-02-13 2012-08-01 プレジデント アンド フェロウズ オブ ハーバード カレッジ 翻訳開始阻害剤としての３−３−二置換オキシインドール
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
KR20060130781A (ko) * 2004-04-08 2006-12-19 토포타겟 에이/에스 다이페닐 인돌-2-온 화합물 및 암 치료에 있어서의 그의용도
JP2009510066A (ja) 2005-09-29 2009-03-12 ワイス 血管運動症状（ｖｍｓ）の治療のためのモノアミン再取り込みのモジュレータである１−（１ｈ−インドール−１−イル）−３−（メチルアミノ）−１−フェニルプロパン−２−オール誘導体および関連の化合物
PE20080655A1 (es) 2006-08-24 2008-07-14 Wyeth Corp Proceso para preparar derivados de indolinona fenilaminopropanol
US20100029646A1 (en) 2006-12-11 2010-02-04 Topo Target A/S Prodrugs of diphenyl ox-indol-2-one compounds
WO2008129075A1 (en) * 2007-04-24 2008-10-30 Topotarget A/S Substituted 3-(4-hydroxyphenyl)-indolin-2-one-compounds
US7858666B2 (en) 2007-06-08 2010-12-28 Mannkind Corporation IRE-1α inhibitors
WO2010109008A1 (en) 2009-03-26 2010-09-30 Topotarget A/S Prodrugs of substituted 3-(4-hydroxyphenyl)-indolin-2-ones
WO2014047437A1 (en) 2012-09-20 2014-03-27 President And Fellows Of Harvard College 3-3-di-substituted-oxindoles as inhibitors of translation initiation
US9316631B1 (en) 2012-10-19 2016-04-19 Whitehead Institute For Biomedical Research ER-stress inducing compounds and methods of use thereof
EP2945646A4 (en) * 2013-01-18 2016-09-21 David J Shapiro ESTROGEN RECEPTOR INHIBITORS
JP6806562B2 (ja) 2013-03-15 2021-01-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ｅＩＦ２α経路の調節因子
LT3004090T (lt) 2013-05-28 2018-01-10 Astrazeneca Ab Cheminiai junginiai
CR20210060A (es) 2018-07-03 2021-04-08 Univ Illinois Activadores de la respuesta a proteínas desplegadas

Also Published As

Publication number Publication date
KR20210027382A (ko) 2021-03-10
CL2020003423A1 (es) 2021-05-14
SG11202012902WA (en) 2021-01-28
MA53105A (fr) 2021-05-12
ECSP20084330A (es) 2021-01-29
CN112423743A (zh) 2021-02-26
PH12020552223A1 (en) 2021-06-28
DOP2020000256A (es) 2021-03-15
BR112020025591A2 (pt) 2021-03-23
US20210276951A1 (en) 2021-09-09
US20200190029A1 (en) 2020-06-18
PE20210662A1 (es) 2021-03-31
CA3103958A1 (en) 2020-01-09
EA202190146A1 (ru) 2021-04-27
EP3817741A4 (en) 2022-07-06
CO2020016690A2 (es) 2021-01-18
JP2021529757A (ja) 2021-11-04
IL279429A (en) 2021-01-31
JOP20200344A1 (ar) 2020-12-31
WO2020009958A1 (en) 2020-01-09
US20210340100A1 (en) 2021-11-04
US11046647B2 (en) 2021-06-29
EP3817741A1 (en) 2021-05-12
AU2019299221A1 (en) 2021-02-04
CR20210060A (es) 2021-04-08
US11584718B2 (en) 2023-02-21

Similar Documents

Publication Publication Date Title
MX2021000043A (es) Activadores de la respuesta a proteinas desplegadas.
MX2020011747A (es) Terapias genicas para los trastornos lisosomales.
PH12018502429A1 (en) Antibody molecules for cancer treatment
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
CL2018002683A1 (es) Antígeno prostático específico de membrana dirigido a agentes de alta afinidad para la endo radio terapia del cáncer de próstata
WO2018140831A3 (en) Tumor targeting conjugates and methods of use thereof
MX2020011748A (es) Terapias genicas para los trastornos lisosomales.
MX2020011745A (es) Terapias genicas para los trastornos lisosomales.
MX2019008208A (es) Métodos para tratar el cáncer con anticuerpos anti-tim-3.
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
ZA201707869B (en) Anti-ntb-a antibodies and related compositions and methods
MX2019008158A (es) Terapia de combinacion para el tratamiento del cancer.
EA201792520A2 (ru) Способы и композиции для определения резистентности к терапии, направленной на андрогенный рецептор
MX2019009848A (es) Proteínas que se unen a her2, nkg2d y cd16.
MX2020012091A (es) Composiciones anti-cd24 y usos de las mismas.
MX2022010638A (es) Inhibidores de pde9 para el tratamiento de enfermedades perifericas.
SA519410320B1 (ar) مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل
WO2018138032A3 (en) NKp46 BINDING AGENTS
CO2022007814A2 (es) Ligandos de la pseudoquinasa tyk2
MX2019009541A (es) Proteinas que se unen a psma, nkg2d y cd16.
EA202090387A1 (ru) Белки, связывающие nkg2d, cd16 и flt3
MX2019009943A (es) Proteínas que se unen a gd2, nkg2d y cd16.
MX2021005377A (es) Terapias dirigidas a cdcp1.
MX2021007235A (es) Tubulisinas y conjugados de proteina-tubulisina.
EA201990370A1 (ru) Терапия рака, связанная с crebbp